Insights: DrugPatentWatch - Find Your Next Blockbuster

Check out this Bloomberg Law article where DrugPatentWatch shows how the number of patent challenges is increasing, while the number of challengers of each patent is also increasing. Why might this be a problem? Read more at https://news.bloomberglaw.com/ip-law/rush-for-generic-go-ahead-on-novel-drugs-roils-pharma-industry

Source

Check out the latest issue of Lab Manager where I discuss my interest in informatics, the complexities of informatics for today’s scientists, and some of the tools available. https://www.labmanager.com/ask-the-expert/trends-in-informatics-22895

Source

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate new generic launches on day-181 Tentative Approvals Identify first generic entrants Authorized Generic Drugs Let us know if there are any other features we can […]

Source

Let DrugPatentWatch build custom dashboards and reports to take the load off of your team. We can ensure the production of accurate, objective, and timely intelligence to help you quickly access the information you need to make better decisions. Examples Upcoming loss-of-exclusivity and generic entry Recent patents & clinical trials in a therapeutic category Recent […]

Source

This article was originally published by Hermann Mucke & Peter Mucke in Future Drug Discovery under a Attribution-NonCommercial-NoDerivatives 4.0 Unported License. https://doi.org/10.4155/fdd-2020-0001. Drug developers require access to scientific information in as close to real time as possible. The commonly employed formal sources are peer-reviewed journals and conference presentations. Another extremely important information source, the intellectual […]

Source

In a recent court ruling, the U.S. Court of Appeals for the Federal Circuit (CAFC) denied a petition to rehear arguments regarding the invalidity of patent claims containing the phrase ‘consisting entirely of‘. As described by Patently-O and IP Watchdog, the indefiniteness of claims containing ‘consisting entirely of‘ fails to satisfy the requirement that a […]

Source

One of our clients, the Belarus Republican Scientific and Technical Library recently posted an article on how they support innovation. They open with the statement that “The novelty, effectiveness and practical application of the results of scientific research largely depend on the completeness and quality of information support.” To provide information resources for their constituents, […]

Source

Here’s a copy of the recent talk on Evaluating innovative portfolios and preparing for branded, 505(b)(2), and generic competition. It’s based on the book Make Better Decisions, which distills insights gained from more than two decades of providing guidance to biopharmaceutical companies.

Source

DrugPatentWatch was used in a recent research study on branded drug sales following generic entry. In this paper, authors Jeffrey Fujimoto, Daniel M Tien, Sophie Snyder, Jeppe A Hertz, and Stuart Schweitzer analyzed the effect of patent expiration of the first innovative drug in a therapeutic class on competitor sales within the same therapeutic class […]

Source

DrugPatentWatch serves companies across the drug development-delivery sector. A common request among drug manufacturers, payers, and suppliers alike is anticipation of which branded drugs will face generic competition, and when…

Source